Application of pharmacokineticโpharmacod
โ
Evelyn D. Lobo; David M. Soda; Joseph P. Balthasar
๐
Article
๐
2003
๐
John Wiley and Sons
๐
English
โ 263 KB
We have shown that intravenous (i.v.) administration of anti-methotrexate (MTX) antibodies (AMAb) reduces the systemic exposure of intraperitoneal (i.p.) MTX therapy, and we have proposed that AMAb effects on MTX systemic exposure would allow a reduction in MTX-induced systemic toxicity (i.e., produ